Closed Loop In Pregnancy: evaluation of the gut absorption rate of glucose during an evening meal and breakfast in women with type 1 diabetes throughout pregnancy

Submission date	Recruitment status	Prospectively registered
03/06/2009	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
07/10/2009	Completed	[X] Results
Last Edited	Condition category	[] Individual participant data
20/11/2012	Nutritional, Metabolic, Endocrine	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Helen R Murphy

Contact details

University of Cambridge Metabolic Research Laboratories Level 4, Institute of Metabolic Science Box 289, Addenbrookes Hospital Hills Road Cambridge United Kingdom CB2 0QQ +44 (0)1223 769079 hm386@medschl.cam.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Version 1.3 Feb 9th 2009

Study information

Scientific Title

Evaluation of the gut absorption rate of glucose during an evening meal and breakfast: a prospective three-centre observational cohort study in pregnant women with type 1 diabetes

Acronym

CLIP - 01

Study objectives

We aim to evaluate whether estimates of glucose absorption rates differ according to the meal type and composition (i.e., breakfast versus evening meal) and according to gestational age during pregnancy. This evaluation will inform the future development of insulin dose adjustment algorithms for use in closed loop systems during pregnancy in women with type 1 diabetes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Cambridgeshire 1 Research Ethics Committee approved on the 16th December 2008 (ref: 08 /H0304/128)

Study design

Prospective multicentre observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Other

Study type(s)

Diagnostic

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Pregnant women with pre-existing type 1 diabetes

Interventions

The same study protocol will be performed on two occasions during early (12 - 16 weeks gestation) and late (28 - 32 weeks gestation) pregnancy. On each occasion participants will eat a tracer-enriched, more slowly-absorbed evening meal, followed by an overnight stay with a tracer enriched, more rapidly absorbed breakfast meal the next morning. A variable subcutaneous (SC) insulin infusion will continue throughout using algorithm control aiming to maintain plasma glucose between 3.5 - 7.8 mmol/L.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Document the changes in gut absorption of a more slowly absorbed medium sized evening meal and a more rapidly absorbed medium sized breakfast meal during pregnancy by the model-based analysis of the data using computational approach previously described by Hovorka et al. The gut absorption rates will be compared using the root mean square error (RMSE).

Secondary outcome measures

Metrics obtained by modelling of tracer glucose:

- 1. BIOmod*: meal bioavailability
- 2. Tmax, mod*: time-to-maximum of the model-derived gut absorption
- 3. T25%, mod*, T50%, mod*, T75%, mod*: time to 25%, 50%, and 75% of the model-derived gut absorption
- 4. AUC0-420, mod*: the area-under-curve of the model-derived gut absorption

Analysis of plasma glucose:

5. Cmax,PG, tmax, PG: the concentration-time profile of plasma glucose concentration following meal digestion/start of glucose infusion

Analysis of plasma insulin:

6. AUCPI(0-240), Cmax, PI, tmax, PI for the concentration-time profiles of plasma insulin

Overall study start date

20/03/2009

Completion date

20/03/2010

Eligibility

Key inclusion criteria

- 1. Signed informed consent obtained before study-related activities. Study-related activities are any procedure that would not have been performed during standard medical care.
- 2. The participant is between 16 and 44 years of age (inclusive)
- 3. The participant has type 1 diabetes, as defined by World Health Organization (WHO) for at least 12 months and has had a viable singleton pregnancy confirmed by ultrasound
- 4. The participant has been on insulin pump or multiple daily injection (MDI) therapy for at least 6 months
- 5. The participant is able and willing to use a real time continuous sensor

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

12

Key exclusion criteria

- 1. Non-type 1 diabetes mellitus including those secondary to chronic disease
- 2. Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results such as coeliac disease or untreated hypothyroidism
- 3. Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and monoamine oxidase (MAO) inhibitors
- 4. Known or suspected allergy against insulin
- 5. Women with clinically significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator
- 6. Documented gastroparesis
- 7. Very poor glycaemic control i.e. HbA1c greater than or equal to 10%
- 8. Significant obesity, i.e., body mass index (BMI) at booking greater than 35 kg/m^2
- 9. Total daily insulin dose greater than 1.5 IU/kg at booking
- 10. Women who have conceived with in-vitro fertilisation (IVF) or assisted reproductive techniques

Date of first enrolment

20/03/2009

Date of final enrolment

20/03/2010

Locations

Countries of recruitment

England

United Kingdom

Study participating centre University of Cambridge Metabolic Research Laboratories

Cambridge United Kingdom CB2 0QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge (UK)

Sponsor details

Box 277
Addenbrookes Hospital
Hills Road
Cambridge
England
United Kingdom
CB2 0QQ
+44 (0)1223 348491
louise.stockley@addenbrookes.nhs.uk

Sponsor type

Hospital/treatment centre

Website

http://www.addenbrookes.org.uk

ROR

https://ror.org/04v54gj93

Funder(s)

Funder type

Charity

Funder Name

Diabetes UK (UK) (ref: BDA 07/0003551)

Alternative Name(s)

DIABETES UK LIMITED, British Diabetic Association

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

National Institute for Health Research (NIHR) (UK) - Post-Doctoral Fellowship (ref: PDF/08/01/036)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2012		Yes	No
Results article	results	01/10/2012		Yes	No